To describe the safety of this vaccine following one dose immunization in adults, adolescent, children and infants.~To assess immunogenicity following one dose of Vi-DT vaccine immunization. To compare the safety and immunogenicity of Vi-DT to Vi polysaccharide vaccine in adults, adolescents, and children groups.~To compare the safety and immunogenicity of Vi-DT to IPV vaccine in infants groups.~Kinetics of Vi-specific IgG antibodies up to 6 months and 1 year after administration of 1 dose of vaccine.~To evaluate the safety and immunogenicity of Vi-DT co-administered with MR vaccine in infants (≥ 9months -23 months old).~To evaluate the safety and immunogenicity of MR vaccine co-administered with Vi-DT vaccine in infants (≥ 9months -23 months old).
This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.